Results 111 to 120 of about 7,383 (189)

Cell shape sensing licenses dendritic cells for homeostatic migration to lymph nodes. [PDF]

Nat Immunol
Alraies Z, Rivera CA, Delgado MG, Sanséau D, Maurin M, Amadio R, Maria Piperno G, Dunsmore G, Yatim A, Lacerda Mariano L, Kniazeva A, Calmettes V, Sáez PJ, Williart A, Popard H, Gratia M, Lamiable O, Moreau A, Fusilier Z, Crestey L, Albaud B, Legoix P, Dejean AS, Le Dorze AL, Nakano H, Cook DN, Lawrence T, Manel N, Benvenuti F, Ginhoux F, Moreau HD, P F Nader G, Piel M, Lennon-Duménil AM.   +33 more
europepmc   +1 more source

Gustave Moreau 1826-1898

, 1913
openaire   +1 more source

Increased c-MYC Expression Associated with Active IGH Locus Rearrangement: An Emerging Role for c-MYC in Chronic Lymphocytic Leukemia. [PDF]

Cancers (Basel)
Guiyedi K, Parquet M, Aoufouchi S, Chauzeix J, Rizzo D, Al Jamal I, Feuillard J, Gachard N, Peron S.   +8 more
europepmc   +1 more source

AI as a Helper: Leveraging Generative AI Tools Across Common Parts of the Creative Process. [PDF]

J Intell
Chompunuch S, Lubart T.
europepmc   +1 more source

La Esquizofrenia Simbólica de lo Femenino en Julián del Casal y Gustave Moreau. [PDF]

, 2007
Gallardo Saborido, Emilio José
core  

El fracaso de la revolución: la imagen de la mujer en el arte europeo de fin de siglo [PDF]

, 2012
Romero Rodríguez, Juan Alberto
core  

Jean-Pierre Duqette, Flaubert ou l’architecture du vide, Montréal, Presse de l’Université de Montréal, 1972, 181 p. [PDF]

, 1972
Gothot-Mersch, Claudine
core   +1 more source

Salome in literature and music [PDF]

, 2014
Danfeng, Jin
core   +1 more source

Single-cell multiplex approaches deeply map ON-target CRISPR-genotoxicity and reveal its mitigation by palbociclib and long-term engraftment

Boutin J, Fayet S, Marin V, Bergès C, Riandière M, Toutain J, Lamrissi-Garcia I, Thibault C, Cappellen D, Dabernat S, Poulet A, Francillette M, Droin N, Debeissat C, Brunet de la Grange P, Moreau-Gaudry F, Bedel A.   +16 more
europepmc   +1 more source

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. [PDF]

Oncotarget, 2018
Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.   +23 more
europepmc   +1 more source